REGENTIS BIOMATERIALS LTD.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Regentis Biomaterials
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions designed to restore health and improve patient quality of life. The company focuses on orthopedic therapies utilizing its Gelrin platform, which employs degradable hydrogel implants to regenerate damaged or diseased cartilage. Its primary product candidate is GelrinC, an acellular, off-the-shelf hydrogel cured into an implant to treat painful articular knee cartilage injuries. GelrinC serves human patients suffering from knee cartilage damage and targets European markets through planned partnerships.
The company operates internationally, having received a CE mark device approval in Europe for GelrinC in 2017. While it currently lacks European strategic partners, it actively seeks future collaborations across Europe to commercialize its technology. Regentis Biomaterials conducts its management and corporate operations from its principal executive offices and headquarters located at 60 Medinat Hayehudim, 4676652, Israel.
Summary of the business section of Regentis Biomaterials's latest annual report, written by StockData.
Company profile
Company
- Legal name
- REGENTIS BIOMATERIALS LTD.
- Headquarters
- Or Akiva, Israel
- Address
- 12 Ha'Ilan Street, Northern Industrial, Zone, P.O. Box 260
- Phone
- 30600
- Website
- regentis.co.il
- Employees
- 3, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- RGNT
- Exchange
- NYSE
- Shares outstanding
- 5M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1912966
- CUSIP
- 001219096
- ISIN
- US0012190965
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ehud Geller | Chief Executive Officer, Director | – |
| Galit Reske | Chief Medical Officer | – |
| Arie Gordashnikov | Chief Accounting Officer | – |
| Ori Gon | Chief Financial Officer | – |
| Susan PHD Alpert MD | Director | – |
| Pini Ben-Elazar | Director | 128,666 |
| Efraim Cohen-Arazi | Director | – |
| Jeff Dykan | Director | 270,473 |
| Keith Valentine | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 9, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |